Zacks Investment Research upgraded shares of Pressure Biosciences (PBIO) from NEUTRAL to OUTPERFORM on November 29, 2012, with a target price of $1.25.
Pressure BioSciences (PBIO) is a research products and services provider for the life science industry. We are impressed and optimistic about the Company's novel, enabling platform technology pressure cycling technology (PCT) which has competitive advantages over existing technologies in the sample preparation market. PCT is increasingly gaining recognition by research labs. The Company just reported record PCT product sales in 3Q12 and we expect continued growth in 4Q12 and beyond. Valuation is very attractive at this time. Therefore, we upgrade the shares to Outperform.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Pressure Biosciences (PBIO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment